SecBot SecBot
SECBOTREPLAY Home › Report › DGX

DGX · Quest Diagnostics reported Q2 2026 EPS of $3.12, a 9.0% beat vs the…

Quest Diagnostics · PRESS-RELEASE filed Sep 9, 2026 at 16:01 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Sep 9, 2026 at 16:01 ET

Quest Diagnostics reported Q2 2026 EPS of $3.12, a 9.0% beat vs the $2.86 consensus, and announced a partnership with Apple to offer lab testing through the Apple Health app. The EPS beat is notable, but the Apple Health integration is a long-term consumer growth catalyst with no immediate financial impact disclosed.

  • Q2 2026 EPS of $3.12 beat consensus of $2.86 by 9.0%
  • Revenue not explicitly stated in the provided filing document; set to null
  • Announced partnership with Apple to offer a 50+ biomarker lab test panel via the Apple Health app later this year
  • The lab panel will be available for $119 at approximately 2,000 Quest patient service centers

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access